Modified simultaneous integrated boost radiotherapy for large retroperitoneal malignant tumor: A case report

• Published in: Oncology letters 2015-06, Vol.9 (6), p.2520-2524
• Main Authors: NOMIYA, TAKUMA, AKAMATSU, HIROKO, HARADA, MAYUMI, OTA, IBUKI, HAGIWARA, YASUHITO, ICHIKAWA, MAYUMI, MIWA, MISAKO, MIZUTANI, MASAOMI, KATO, TOMOYUKI, NAGAOKA, AKIRA, TOMITA, YOSHIHIKO, NEMOTO, KENJI
• Format: Article
• Language: English
• Subjects: Abdomen; Antigens; Brain cancer; Cancer; Cancer therapies; Care and treatment; Case reports; Chemotherapy; clinical trial; Diagnosis; Gastric cancer; Methods; Oncology; Pancreatic cancer; Patient outcomes; Patients; Radiation therapy; Radiotherapy; retroperitoneal neoplasm; Surgery; technique; Tumors
• ISSN: 1792-1074; 1792-1082
• DOI: 10.3892/ol.2015.3095

The current study reports the case of a large retroperitoneal tumor treated with modified simultaneous integrated boost (SIB) radiotherapy. A 45-year-old female presented to the emergency department complaining of left abdominal pain and fever. A computed tomography scan detected a retroperitoneal tumor of 12×16×16 cm, and a biopsy revealed a poorly-differentiated adenocarcinoma. The patient was diagnosed with a large adenocarcinoma originating from the left ureter, with no distant metastasis. Due to the patient's poor physical condition, surgery was not recommended, and the patient was referred to the Department of Radiation Oncology (Yamagata University Hospital, Yamagata, Japan). Modified SIB radiotherapy was administered following the acquisition of written consent from the patient. The total irradiation dose to the center of the tumor and to the surrounding healthy tissue was ∼96 Gy/33 fractions and 3 years with no complications. Modified SIB radiotherapy may be safely administered, with favorable outcomes. Complete recovery can be achieved with this technique, even in a patient with a large radioresistant tumor.